Clinical trials: Unresectable Locally Advanced NSCLC
Non Small Cell Lung Cancer
A Study to Compare Uliledlimab Combined With Toripalimab, Toripalimab Monotherapy, and Pembrolizumab Monotherapy in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic PD-L1- and CD73- Selected Non-Small Cell Lung Cancer
This is a Phase II/III, randomized, open-label, active-controlled, multicenter study to compare intravenous uliledlimab combined with toripalimab, toripalimab monotherapy, and pembrolizumab monotherapy in patients with previously…
- Trial name
- NCT06984588
- Testing
- Uliledlimab, Toripalimab, Pembrolizumab
- Where
- 64 sites in China
- Volunteers
- 450 people
- Sponsor
- TJ Biopharma Co., Ltd.
Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma
Trametinib and Pembrolizumab in Treating Patients With Recurrent Non-small Cell Lung Cancer That Is Metastatic, Unresectable, or Locally Advanced
This phase Ib/II trial studies the side effects and best dose of trametinib when given together with pembrolizumab and to see how well they work in treating patients with non-small cell lung cancer that has come back and spread…
- Conditions
- Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8
- Trial name
- NCT03225664
- Testing
- Pembrolizumab, Pharmacokinetic Study, Trametinib
- Where
- 2 sites in United States
- Volunteers
- 37 people
- Sponsor
- M.D. Anderson Cancer Center
Recurrent Non-small Cell Lung Cancer, Recurrent Prostate Cancer
GTI-2040 and Docetaxel in Treating Patients With Recurrent, Metastatic, or Unresectable Locally Advanced Non-Small Cell Lung Cancer, Prostate Cancer, or Other Solid Tumors
Phase I/II trial to study the effectiveness of combining GTI-2040 with docetaxel in treating patients who have recurrent, metastatic, or unresectable locally advanced non-small cell lung cancer, prostate cancer, or other solid…
- Conditions
- Recurrent Non-small Cell Lung Cancer, Recurrent Prostate Cancer, Stage III Prostate Cancer, Stage IIIA Non-small Cell Lung Cancer
- Trial name
- NCT00074022
- Testing
- GTI-2040, docetaxel, laboratory biomarker analysis
- Where
- Canada
- Volunteers
- 48 people
- Sponsor
- National Cancer Institute (NCI)
Non-small-cell Lung Cancer
Nimotuzumab Combined With Chemoradiotherapy for Unresectable Locally Advanced Squamous Cell Lung Cancer
This Phase II randomized study is to determine the efficacy and toxicity of Nimotuzumab in combined with chemoradiotherapy for unresectable,local advanced squamous cell lung cancer.
- Trial name
- NCT02577341
- Testing
- Nimotuzumab, docetaxel and cisplatin, daily RT to the chest
- Where
- China
- Volunteers
- 122 people
- Sponsor
- Sun Yat-sen University
Carcinoma, Non-Small-Cell Lung
Nab-Paclitaxel in Combination With Carboplatin as First-line Therapy in Patients With NSCLC
This is a single-arm non-interventional study (NIS) to evaluate the effectiveness, safety and quality of life (QoL) in patients with advanced NSCLC receiving the combination of nab-paclitaxel and carboplatin as first line…
- Trial name
- NEPTUN (NCT02799862)
- Testing
- Nab-Paclitaxel, Carboplatin
- Where
- Germany
- Volunteers
- 408 people
- Sponsor
- iOMEDICO AG
Non-Small Cell Carcinoma of Lung, Locally Advanced
Becotatug Vedotin + Pucotenlimab+Platinum Induction and Sequential CCRT for Unresectable LA NSCLC
This is a prospective, single-arm phase II clinical study enrolling patients with locally advanced unresectable non-small cell lung cancer.
- Trial name
- NCT07882940
- Testing
- Becotatug Vedotin (MRG003)+pucotenlimab+platinum, radiotherapy
- Volunteers
- 24 people
- Sponsor
- Sun Yat-sen University
Non-small Cell Lung Cancer
Erlotinib Combined With Radiotherapy in Patients With Non-resectable Locally Advanced Non-small Cell Lung Cancer (LA-NSCLC)
Concomitant chemoradiotherapy is the standard treatment of locally advanced,non-resectable, non-small cell lung cancer (NSCLC). However,the optimal chemotherapy regimen is still controversial.The objective of this study was to…
- Trial name
- RT0901 (NCT01091376)
- Testing
- Erlotinib, Thoracic radiotherapy
- Where
- China
- Volunteers
- 75 people
- Sponsor
- Zhejiang Cancer Hospital
Stage III Non-small Cell Lung Cancer
Construction of CT Radiomics Model for Predicting the Efficacy of Immunotherapy in Patients With Stage III NSCLC
Consolidation immunotherapy of immune checkpoint inhibitor (ICI) following chemoradiotherapy (CRT) is the current standard of care for patients with unresectable locally advanced non-small cell lung cancer (NSCLC) as it improves…
- Trial name
- NCT04984148
- Testing
- CT
- Where
- China
- Volunteers
- 70 people
- Sponsor
- Guangdong Provincial People's Hospital
NSCLC (Advanced Non-small Cell Lung Cancer)
EMPATHY NSCLC: European Registry for Plasma-Based Molecular Profiling in Advanced NSCLC Patients
The goal of this registry is to capture real-world data from plasma- and tissue-based molecular profiling, treatments, outcomes and patient-reported outcomes from patients with advanced or metastatic non-small cell lung cancer…
- Trial name
- EMPATHY NSCLC (NCT07096258)
- Where
- 4 sites in France, Italy and 2 more
- Volunteers
- 1,000 people
- Sponsor
- Hedera Dx SA
Non-Small Cell Lung Cancer
Docetaxel & Oxaliplatin in Combination With Bevacizumab as First-Line Treatment in Subjects With Non-Small Cell Lung Cancer (NSCLC)
The purpose of this study was to see how well three investigational drugs worked together in preventing progression of the disease.
- Trial name
- NCT00356122
- Testing
- Docetaxel, Oxaliplatin, Bevacizumab
- Where
- United States
- Volunteers
- 53 people
- Sponsor
- Sanofi
Cancer, Tumor, Solid
Study of JK08 in Patients with Unresectable Locally Advanced or Metastatic Cancer
This is a Phase 1/2, open-label, multi-center, first-in-human, dose escalation and cohort expansion study evaluating multiple doses and schedules of subcutaneously administered JK08 in patients with unresectable locally, advanced…
- Conditions
- Cancer, Tumor, Solid, Advanced Solid Tumor, Metastatic Cancer
- Trial name
- NCT05620134
- Testing
- JK08, Pembrolizumab, Lenvatinib Pill
- Where
- 11 sites in Belgium, Spain
- Volunteers
- 263 people
- Sponsor
- Salubris Biotherapeutics Inc
Non-small Cell Lung Cancer
ctDNA as a Biomarker for Treatment in Advanced NSCLC
The dynamic monitoring of circulating tumor DNA aims to evaluate the response and progression-free survival of short-course chemotherapy (2 cycles) combined with immunotherapy in patients with locally advanced unresectable or…
- Trial name
- NCT05486988
- Testing
- Immunotherapy, Chemotherapeutic Agent, Chemotherapy
- Where
- China
- Volunteers
- 500 people
- Sponsor
- Fuzhou General Hospital
NSCLC (Non-small Cell Lung Cancer)
A Study of AK104 in Subjects With Unresectable Locally Advanced NSCLC
This study compares the efficacy and safety of AK104 versus Sugemalimab as consolidation therapy in patients with unresectable, locally advanced NSCLC who have not progressed following concurrent or sequential chemoradiotherapy.
- Trial name
- NCT06617416
- Testing
- Cadonilimab (AK104), Sugemalimab
- Where
- China
- Volunteers
- 560 people
- Sponsor
- Akeso
PD-L1-positive, Locally Advanced (Unresectable Stage IIIB/C) or Metastatic NSCLC
Trial to Evaluate Acasunlimab and Pembrolizumab Combination Superiority Over Standard of Care Docetaxel in Non-Small Cell Lung Cancer (ABBIL1TY NSCLC-06)
This is a multicenter, randomized, open-label, international, Phase 3 trial to evaluate the efficacy and safety of acasunlimab in combination with pembrolizumab versus docetaxel (standard of care) in participants with locally…
- Trial name
- NCT06635824
- Testing
- Acasunlimab, Pembrolizumab, Docetaxel
- Where
- 247 sites in United States, Argentina and 25 more
- Volunteers
- 191 people
- Sponsor
- Genmab
Non Small Cell Lung Cancer
Lung Cancer With Copanlisib and Durvalumab
The current study focuses on unresectable stage III non-small cell lung cancer (NSCLC) patients who are starting Durvalumab consolidation after concurrent chemoradiation with a goal of cure.
- Trial name
- LCD (NCT04895579)
- Testing
- Durvalumab, Copanlisib
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Zhonglin Hao
Carcinoma, Non-Small-Cell Lung
Study of Pembrolizumab/Vibostolimab (MK-7684A) in Combination With Concurrent Chemoradiotherapy Followed by Pembrolizumab/Vibostolimab Versus Concurrent Chemoradiotherapy Followed by Durvalumab in Participants With Stage III Non-small Cell Lung Cancer (MK-7684A-006)
Researchers are looking for new ways to treat people with locally advanced non-small cell lung cancer (NSCLC). The goal of this study is to learn if people who receive the combination of vibostolimab and pembrolizumab (MK-7684A)…
- Trial name
- KEYVIBE-006 (NCT05298423)
- Testing
- pembrolizumab/vibostolimab, durvalumab, cisplatin
- Where
- 160 sites in United States, Argentina and 23 more
- Volunteers
- 610 people
- Sponsor
- Merck Sharp & Dohme LLC
AIDS-Related Non-Hodgkin Lymphoma, Clinical Stage III Cutaneous Melanoma AJCC v8
Testing the Addition of an Experimental Medication MK-3475 (Pembrolizumab) to Usual Anti-Retroviral Medications in Patients With HIV and Cancer
This phase I trial studies the side effects of pembrolizumab in treating patients with human immunodeficiency virus (HIV) and malignant neoplasms that have come back (relapsed), do not respond to treatment (refractory), or have…
- Conditions
- AIDS-Related Non-Hodgkin Lymphoma, Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Hepatocellular Carcinoma
- Trial name
- NCT02595866
- Testing
- Antiretroviral Therapy, Biopsy, Biospecimen Collection
- Where
- 12 sites in United States
- Volunteers
- 58 people
- Sponsor
- National Cancer Institute (NCI)
Non-Small Cell Lung Cancer, Locally Advanced Non-Small Cell Lung Cancer
Induction Chemoimmunotherapy in Combination With Chemoradiotherapy and Consolidation Immunotherapy in Unresectable Locally Advanced Non-Small Cell Lung Cancer
PIVOT study is a multicenter, phase I/II clinical study designed to evaluate induction chemoimmunotherapy followed by concurrent chemoradiotherapy and consolidation immunotherapy in patients with unresectable locally advanced…
- Conditions
- Non-Small Cell Lung Cancer, Locally Advanced Non-Small Cell Lung Cancer, Unresectable Stage III NSCLC
- Trial name
- NCT07632365
- Testing
- Induction chemoimmunotherapy, Concurrent chemoradiotherapy (cCRT), consolidation immunotherapy
- Where
- China
- Volunteers
- 108 people
- Sponsor
- Shanghai Chest Hospital
Non-Small Cell Lung Cancer Stage III
A Study of CS1001 in Subjects With Stage III Non-Small Cell Lung Cancer
This is a randomized, double-blind, placebo-controlled, multicenter phase III study to evaluate the efficacy and safety of CS1001 in subjects with locally advanced/unresectable (Stage III) non-small cell lung cancer that has not…
- Trial name
- NCT03728556
- Testing
- CS1001 monoclonal antibody
- Where
- China
- Volunteers
- 381 people
- Sponsor
- CStone Pharmaceuticals
Stage III Non-small Cell Lung Cancer, Unresectable
Durvalumab Alone or in Combination With Novel Agents in Subjects With NSCLC
The purpose of this study is to compare the clinical activity of durvalumab alone vs durvalumab in combination with novel agents.
- Trial name
- COAST (NCT03822351)
- Testing
- Durvalumab + Oleclumab, Durvalumab, Durvalumab + Monalizumab
- Where
- 73 sites in United States, Canada and 7 more
- Volunteers
- 189 people
- Sponsor
- MedImmune LLC